Wanted: Cost-Efficient Regulation At CMS; Will McClellan Heed Call?
This article was originally published in The Gray Sheet
Executive Summary
FDA Commissioner Mark McClellan's consistent emphasis on the need to balance medical technology innovation with affordability would serve him well as a CMS administrator